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Introduction {#sec001}
============

Hearing loss leads to a number of issues such as inability to recognize speech, depression, withdrawal, anger, loss of self-esteem, and poor quality of life ([www.healthinaging.org/a-z-topic/hearing-loss](http://www.healthinaging.org/a-z-topic/hearing-loss)). Around 466 million people worldwide have disabling hearing loss, and it is estimated that by 2050, over 900 million people will have disabling hearing loss ([www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss](http://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss)). Thus, hearing loss can have significant emotional and social impact.

Hearing loss may result from genetic causes, complications at birth, certain viral infections, chronic ear infections, exposure to excessive noise, aging, and ototoxic drugs ([www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss](http://www.who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss)). More than 150 drugs such as platinum-based anticancer drugs and aminoglycosides are currently known to ototoxic \[[@pone.0217951.ref001]\]. Ototoxic drugs cause functional impairment and/or cellular degeneration of tissues of the inner ear, and result in sensorineural hearing loss \[[@pone.0217951.ref002]\]. Since the awareness about drug-induced hearing loss (DIHL) has increased among pharmaceutical companies and healthcare professionals, there is greater knowledge about DIHL. To understand the characteristics of DIHL, the time-to-onset profile of DIHL is important. Cisplatin-induced hearing loss usually starts within days to weeks after treatment, and macrolide-induced hearing loss occurs within 2−7 days after the start of treatment \[[@pone.0217951.ref002]\]. However, similar information about other ototoxic drugs, it is not well known.

Spontaneous reporting systems (SRSs) such as the Japanese Adverse Drug Event Report (JADER) database of the Pharmaceuticals and Medical Devices Agency (PMDA) has been used in pharmacovigilance assessments. SRSs have served as valuable tools in post-marketing surveillance as they reflect the realities of clinical practice. Several pharmacovigilance indices, such as reporting odds ratio (ROR), have been developed for drug-associated adverse events (AEs) \[[@pone.0217951.ref003]\]. ROR is a powerful and applicable technique that allows to conduct adjustments through multivariate logistic regression analysis and to control for confounding factors \[[@pone.0217951.ref004]--[@pone.0217951.ref006]\]. Moreover, association rule mining is a new analytical approach for the discovery of previously undetected relationships, including possible risk factors among variables in huge databases \[[@pone.0217951.ref007]--[@pone.0217951.ref009]\]. Finally, the time-to-onset analysis using the Weibull shape parameter (WSP) is a useful tool for AE signal detection \[[@pone.0217951.ref006], [@pone.0217951.ref010]--[@pone.0217951.ref013]\]. However, the AE profiles associated with DIHL in the JADER database have not yet been assessed yet.

To the best of our knowledge, our study was the first to evaluate the risk of DIHL associated with prescription drugs by analyzing the JADER database. We estimated DIHL by determining RORs and conducting multivariate logistic regression analysis, association rule mining, and time-to-onset analysis.

Materials and methods {#sec002}
=====================

Information from the JADER database, which included data recorded from April 2004 to June 2018, were obtained from the PMDA website ([www.pmda.go.jp](http://www.pmda.go.jp)). All data from the JADER database were fully anonymized by the regulatory authority before we accessed them. The structure of the JADER database complies with international safety reporting guidelines (International Council for Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use \[ICH\] E2B). The database consists of four data tables: 1) patient demographic information (DEMO), 2) drug information (DRUG), 3) AEs (REAC), and 4) primary illness (HIST). The JADER database does not contain codes for identifying case reports (A1.11), and therefore, we could not exclude duplicate case reports for the same patient ([www.pmda.go.jp/files/000145474.pdf](http://www.pmda.go.jp/files/000145474.pdf)). In the DRUG table, the causality of each drug was assigned a code according to its association with the AEs, such as a "suspected drug," "concomitant drug," or "interacting drug." The analysis was restricted to reports in which drugs were recorded as a "suspected drug."

Age is recorded in the DEMO table that includes patient demographic data. The following age-related items are entered in the DEMO table: \< 10, 10--19, 20--29, 30--39, 40--49, 50--59, 60--69, 70--79, 80--89, 90--99, or ≥ 100 years; neonate, baby, infant, child, young adult, adult, or elderly; first trimester, second trimester, or third trimester; and unknown. Reports were stratified by age as follows: ≤ 19, 20--39, 40--59, 60--79, and ≥ 80 years. The ≤ 19 years analysis group included the \< 10, 10--19 years, neonate, baby, infant, and child groups. The ≥ 80 years group consisted of the 80--89, 90--99, and ≥ 100 years group. We excluded the items young adult, adult, elderly, first trimester, second trimester, third trimester, and unknown, because these descriptions could not be categorized into precise 20-year intervals.

The AE definitions used in this study corresponded with those in the Medical Dictionary for Regulatory Activities/Japanese version (MedDRA/J, [www.pmrj.jp/jmo/php/indexj.php](http://www.pmrj.jp/jmo/php/indexj.php)) ver. 19.0. The Standardized MedDRA Queries (SMQ) index consists of groupings of MedDRA terms, ordinarily at the preferred term (PT) level, that relate to a defined medical condition in an area of interest. We used 38 preferred terms for DIHL detection based on the SMQ "hearing disorders" (SMQ code: 20000171) ([Table 1](#pone.0217951.t001){ref-type="table"}). The "hearing disorders" SMQ contains 50 preferred terms. We excluded the following 12 terms that are presumably not related to DIHL: disorders associated with inflammation (acoustic neuritis (PT code: 10063162), hemotympanum (PT code: 10063013), middle ear inflammation (PT code: 10065838), myringitis (PT code: 10061302), myringitis bullous (PT code: 10028659), otosalpingitis (PT code: 10033102), and cholesterol granuloma of the middle ear (PT code: 10008649)); hearing disorders associated with hearing aids (bone anchored hearing aid implantation (PT code: 10070723), cochlea implant (PT code: 10009830), and hearing aid therapy (PT code: 10075385)); hyperacusis (PT code: 10020559); and tinnitus (PT code: 10043882). We used the Anatomical Therapeutic Chemical (ATC) Classification System described by the World Health Organization Collaborating Centre for Drug Statistics Methodology for drug definitions ([www.whocc.no/atc_ddd_index/](http://www.whocc.no/atc_ddd_index/)). All generic names of drugs were verified and subsequently linked to the corresponding ATC classification codes. According to the ATC Classification System, drugs related to DIHL were classified into 18 ATC classes ([Table 2](#pone.0217951.t002){ref-type="table"}).
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###### Preferred terms of "hearing disorders" (SMQ [^a)^](#t001fn001){ref-type="table-fn"} code: 20000171) associated with ototoxic drugs in MedDRA [^b)^](#t001fn002){ref-type="table-fn"}.

![](pone.0217951.t001){#pone.0217951.t001g}

  CODE       Preferred Term                                 CODE       Preferred Term
  ---------- ---------------------------------------------- ---------- ----------------------------------------------
  10000526   acoustic stimulation tests abnormal (0 case)   10015544   eustachian tube obstruction (1 case)
  10075083   altered pitch perception (0 case)              10048865   hypoacusis (182 cases)
  10003761   audiogram abnormal (1 case)                    10027582   middle ear adhesions (1 case)
  10003778   auditory disorder (25 cases)                   10062545   middle ear effusion (0 case)
  10003789   auditory recruitment (0 case)                  10027757   mixed deafness (5 cases)
  10048827   autophony (0 case)                             10067587   neurosensory hypoacusis (1 case)
  10010280   conductive deafness (1 case)                   10061327   ossicle disorder (0 case)
  10011878   deafness (518 cases)                           10063643   otoacoustic emissions test abnormal (0 case)
  10052556   deafness bilateral (23 cases)                  10033103   otosclerosis (0 case)
  10011891   deafness neurosensory (108 cases)              10036626   presbyacusis (1 case)
  10011893   deafness occupational (0 case)                 10039191   rinne tuning fork test abnormal (0 case)
  10011894   deafness permanent (0 case)                    10061373   sudden hearing loss (288 cases)
  10011900   deafness transitory (7 cases)                  10045208   tympanic membrane atrophic (0 case)
  10048812   deafness unilateral (43 cases)                 10062218   tympanic membrane disorder (1 case)
  10013032   diplacusis (0 case)                            10045210   tympanic membrane perforation (16 cases)
  10049712   dysacusis (5 cases)                            10063604   tympanic membrane scarring (0 case)
  10014399   electrocochleogram abnormal (0 case)           10045215   tympanometry abnormal (0 case)
  10061462   eustachian tube disorder (0 case)              10045218   tympanosclerosis (0 case)
  10015543   eustachian tube dysfunction (1 case)           10047878   Weber tuning fork test abnormal (0 case)

^a)^ SMQ: Standardized MedDRA Queries

^b)^ MedDRA: Medical Dictionary for Regulatory Activities

10.1371/journal.pone.0217951.t002

###### Number of reports and reporting odds ratio of drug-induced hearing loss [^a)^](#t002fn003){ref-type="table-fn"}.

![](pone.0217951.t002){#pone.0217951.t002g}

  ATC [^b)^](#t002fn004){ref-type="table-fn"} classification   ATC [^b)^](#t002fn004){ref-type="table-fn"} code   Total (n)   Case (n)   ROR [^c)^](#t002fn005){ref-type="table-fn"} (95% CI [^d)^](#t002fn006){ref-type="table-fn"})   Drugs                                                       Total (n)   Case (n)   ROR [^c)^](#t002fn005){ref-type="table-fn"} (95% CI [^d)^](#t002fn006){ref-type="table-fn"})
  ------------------------------------------------------------ -------------------------------------------------- ----------- ---------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------- ----------- ---------- ----------------------------------------------------------------------------------------------
                                                                                                                                                                                                                                        Total                                                       534688      1218       
  Platinum compounds                                           L01XA                                              21661       86         1.8 (1.4−2.2)[\*](#t002fn001){ref-type="table-fn"}                                             cisplatin                                                   8673        58         3.0 (2.3−4.0)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        carboplatin                                                 5281        26         2.2 (1.5−3.2)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        oxaliplatin                                                 8001        8          0.4 (0.2−0.9)
  Sulfonamides (plain)                                         C03CA                                              2913        77         12.6 (10.0−16.0)[\*](#t002fn001){ref-type="table-fn"}                                          furosemide                                                  2710        72         12.6 (9.9−16.1)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        torasemide                                                  247         5          9.1 (3.7−22.1)[\*](#t002fn001){ref-type="table-fn"}
  Interferons                                                  L03AB                                              12785       73         2.6 (2.1−3.3)[\*](#t002fn001){ref-type="table-fn"}                                             peginterferon alfa-2b                                       6866        49         3.2 (2.4−4.3)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        peginterferon alfa-2a                                       3386        13         1.7 (0.98−2.9)
                                                                                                                                                                                                                                        interferon alfa-2b                                          739         4          2.4 (0.9−6.4)
                                                                                                                                                                                                                                        interferon beta natural                                     1553        3          0.8 (0.3−2.6)
                                                                                                                                                                                                                                        interferon alfacon-1                                        90          2          10.0 (2.5−40.5)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        interferon alfa natural                                     354         2          2.5 (0.6−10.0)
  Antivirals for treatment                                     J05AP                                              13134       67         2.3 (1.8−3.0)[\*](#t002fn001){ref-type="table-fn"}                                             ribavirin                                                   10394       62         2.7 (2.1−3.5)[\*](#t002fn001){ref-type="table-fn"}
  of HCV infections                                                                                                                                                                                                                     telaprevir                                                  4257        10         1.0 (0.6−1.9)
                                                                                                                                                                                                                                        sofosbuvir                                                  1865        6          1.4 (0.6−3.2)
                                                                                                                                                                                                                                        simeprevir                                                  2285        3          0.6 (0.2−1.8)
                                                                                                                                                                                                                                        asunaprevir                                                 678         2          1.3 (0.3−5.2)
  Other aminoglycosides                                        J01GB                                              964         58         29.4 (22.4−38.6)[\*](#t002fn001){ref-type="table-fn"}                                          gentamicin                                                  264         30         57.5 (39.2−84.5)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        amikacin                                                    194         11         26.6 (14.4−48.9)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        kanamycin                                                   49          5          50.0 (19.8−126.2)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        isepamicin                                                  93          4          19.7 (7.2−53.9)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        neomycin                                                    85          4          21.7 (7.9−59.3)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        arbekacin                                                   249         3          5.4 (1.7−16.7)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        tobramycin                                                  55          2          16.6 (4.0−68.0)[\*](#t002fn001){ref-type="table-fn"}
  Protein kinase inhibitors                                    L01XE                                              26034       42         0.7 (0.5−0.9)                                                                                  imatinib                                                    4399        11         1.1 (0.6−2.0)
                                                                                                                                                                                                                                        sorafenib                                                   4915        10         0.9 (0.5−1.7)
                                                                                                                                                                                                                                        dasatinib                                                   1255        3          1.0 (0.3−3.3)
                                                                                                                                                                                                                                        erlotinib                                                   2744        3          0.5 (0.2−1.5)
                                                                                                                                                                                                                                        axitinib                                                    878         2          1.0 (0.2−4.0)
                                                                                                                                                                                                                                        lapatinib                                                   731         2          1.2 (0.3−4.8)
                                                                                                                                                                                                                                        nilotinib                                                   1841        2          0.5 (0.1−1.9)
                                                                                                                                                                                                                                        osimertinib                                                 653         2          1.3 (0.3−5.4)
                                                                                                                                                                                                                                        regorafenib                                                 1601        2          0.5 (0.1−2.2)
                                                                                                                                                                                                                                        ruxolitinib                                                 872         2          1.0 (0.3−4.0)
                                                                                                                                                                                                                                        dabrafenib                                                  154         1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        everolimus                                                  3671        1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        gefitinib                                                   2736        1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        trametinib                                                  157         1          −[^\#^](#t002fn002){ref-type="table-fn"}
  Carcineurin inhibitors                                       L04AD                                              16752       38         1.0 (0.7−1.4)                                                                                  ciclosporin                                                 6602        31         2.1 (1.5−3.0)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        tacrolimus                                                  10472       7          0.3 (0.1−0.6)
  Pyrimidine analogues                                         L01BC                                              25158       37         0.6 (0.5−0.9)                                                                                  tegafur, combinations                                       8201        16         0.9 (0.5−1.4)
                                                                                                                                                                                                                                        capecitabine                                                3561        11         1.4 (0.8−2.5)
                                                                                                                                                                                                                                        fluorouracil                                                7796        8          0.4 (0.2−0.9)
                                                                                                                                                                                                                                        cytarabine                                                  1785        1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        gemcitabine                                                 4454        1          −[^\#^](#t002fn002){ref-type="table-fn"}
  Taxanes                                                      L01CD                                              13351       35         1.2 (0.8−1.6)                                                                                  paclitaxel                                                  6900        25         1.6 (1.1−2.4)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        docetaxel                                                   5415        11         0.9 (0.5−1.6)
                                                                                                                                                                                                                                        cabazitaxel                                                 1174        2          0.7 (0.2−3.0)
  Monoclonal antibodies                                        L01XC                                              25555       32         0.5 (0.4−0.8)                                                                                  nivolumab                                                   4419        14         1.4 (0.8−2.4)
                                                                                                                                                                                                                                        trastuzumab                                                 2192        5          1.0 (0.4−2.4)
                                                                                                                                                                                                                                        bevacizumab                                                 9414        5          0.2 (0.1−0.6)
                                                                                                                                                                                                                                        cetuximab                                                   2742        2          0.3 (0.1−1.3)
                                                                                                                                                                                                                                        ipilimumab                                                  545         2          1.6 (0.4−6.5)
                                                                                                                                                                                                                                        rituximab                                                   3979        2          0.2 (0.1−0.9)
                                                                                                                                                                                                                                        mogamulizumab                                               469         1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        ofatumumab                                                  83          1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        pembrolizumab                                               2144        1          −[^\#^](#t002fn002){ref-type="table-fn"}
  Papillomavirus vaccines                                      J07BM                                              2259        32         6.4 (4.5−9.2)[\*](#t002fn001){ref-type="table-fn"}                                             papillomavirus (human types 16, 18)                         1889        23         5.5 (3.6−8.3)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        papillomavirus (human types 6, 11, 16, 18)                  370         9          11.0 (5.7−21.4)[\*](#t002fn001){ref-type="table-fn"}
  Drugs used in electile                                       G04BE                                              870         29         15.4 (10.6−22.5)[\*](#t002fn001){ref-type="table-fn"}                                          tadalafil                                                   401         17         19.7 (12.0−32.0)[\*](#t002fn001){ref-type="table-fn"}
  dysfunction                                                                                                                                                                                                                           sildenafil                                                  478         13         12.4 (7.1−21.5)[\*](#t002fn001){ref-type="table-fn"}
  Other antiepileptics                                         N03AX                                              10021       27         1.2 (0.8−1.7)                                                                                  pregabalin                                                  4659        20         1.9 (1.2−3.0)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        lamotrigine                                                 3446        4          0.5 (0.2−1.4)
                                                                                                                                                                                                                                        levetiracetam                                               1866        2          0.5 (0.1−1.9)
                                                                                                                                                                                                                                        lacosamide                                                  213         1          −[^\#^](#t002fn002){ref-type="table-fn"}
  Carboxamide derivatives                                      N03AF                                              5568        24         1.9 (1.3−2.9)[\*](#t002fn001){ref-type="table-fn"}                                             carbamazepine                                               5568        24         1.9 (1.3−2.9)[\*](#t002fn001){ref-type="table-fn"}
  Glycopeptide antibacterials                                  J01XA                                              2658        21         3.5 (2.3−5.4)[\*](#t002fn001){ref-type="table-fn"}                                             vancomycin                                                  1947        20         4.6 (3.0−7.2)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        teicoplanin                                                 805         3          1.6 (0.5−5.1)
  Macrolides                                                   J01FA                                              5769        20         1.5 (0.98−2.4)                                                                                 azithromycin                                                1434        11         3.4 (1.9−6.2)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        clarithromycin                                              4066        5          0.5 (0.2−1.3)
                                                                                                                                                                                                                                        erythromycin                                                82          2          11.0 (2.7−44.7)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        spiramycin                                                  2           1          −[^\#^](#t002fn002){ref-type="table-fn"}
                                                                                                                                                                                                                                        telithromycin                                               293         1          −[^\#^](#t002fn002){ref-type="table-fn"}
  Other quaternary ammonium                                    M03AC                                              400         16         18.5 (11.2−30.6)[\*](#t002fn001){ref-type="table-fn"}                                          pancuronium                                                 30          13         338.5 (164.1−698.5)[\*](#t002fn001){ref-type="table-fn"}
  compounds                                                                                                                                                                                                                             vecuronium                                                  376         3          3.5 (1.1−11.0)[\*](#t002fn001){ref-type="table-fn"}
  Pneumococcal vaccines                                        J07AL                                              3011        14         2.1 (1.2−3.5)[\*](#t002fn001){ref-type="table-fn"}                                             pneumococcus, purified polysaccharides antigen              1457        11         3.4 (1.8−6.1)[\*](#t002fn001){ref-type="table-fn"}
                                                                                                                                                                                                                                        pneumococcus, purified polysaccharides antigen conjugated   1566        3          0.8 (0.3−2.6)

\* The lower limit of 95% CI \> 1.

^\#^ Number of cases \< 2.

^a)^ The number of reports stratified by ATC code or each drug name was calculated.

^b)^ ATC: Anatomical Therapeutic Chemical

^c)^ ROR: reporting odds ratio

^d)^ CI: confidence interval

The authorized pharmacovigilance index ROR \[[@pone.0217951.ref003]\] was calculated using a two-by-two contingency table pertaining to the presence or absence of a particular drug and AE in the case reports. ROR is the ratio of odds of reporting an AE (DIHL-related AE) versus all other events associated with the given drug compared to the reporting odds for all other drugs in the JADER database ([Fig 1](#pone.0217951.g001){ref-type="fig"}) \[[@pone.0217951.ref003]\]. ROR was expressed as a point estimate with a 95% confidence interval (CI) \[[@pone.0217951.ref004]\]. Signals were considered statistically significant, if the lower limit of the 95% CI was above 1; at least two cases were required for analysis \[[@pone.0217951.ref014]\].

![Two by two contingency table for analysis.](pone.0217951.g001){#pone.0217951.g001}

We refined the ROR signal with a dedicated correction to detect possible confounders in the database \[[@pone.0217951.ref015]\]. Furthermore, ROR was adjusted using a multivariate logistic regression model. To calculate the adjusted ROR, only reports with complete information regarding reporting year, sex, and age were extracted from the JADER database. The following formula was used: $${\text{log}\left( {odds} \right)} = \beta_{0} + \beta_{1}Y + \beta_{2}S + \beta_{3}A + \beta_{4}S*A$$

Reporting year (Y), sex (S), and the age-stratified group (≤ 19 years, 20--39 years, 40--59 years, 60--79 years, and ≥ 80 years) (A) were defined as independent variables. The dependent variable was a binary response to the absence or presence of DIHL in each report. To comparatively evaluate the effect of factors, we selected explanatory variables using a stepwise method \[[@pone.0217951.ref016], [@pone.0217951.ref017]\] and a significance level of 0.05 (forward and backward). The contribution of selected variables in the final model was evaluated. A likelihood ratio test was used to assess the influence of explanatory variables.

A mosaic plot of the contingency table was constructed using the age-category (X) and ATC classification of DIHL-related drugs (Y). The proportions on the x-axis represent the number of observations for each level of the X variable. The mosaic plot is divided into rectangles, and the vertical length of a rectangle is proportional to the size of the Y variable at each level of the X variable.

We evaluated drug dose-dependency using patient demographic data (DEMO) and drug information (DRUG). We estimated the daily dose utilizing the daily dose per square meter (mg/m^2^) based on body weight and height against each case in the JADER database. Next, we compared the doses of suspected drugs between patients with and without DIHL using Student's *t*-test.

Association rule mining is a common technique used to identify associations among numerous variables. Given a set of transactions ***T*** (each transaction is a set of items), an association rule can be expressed as X \[lhs: left-hand-side, the antecedent of the rule\] → Y \[rhs: right-hand-side, the consequent of the rule\], where X and Y are mutually exclusive sets of items \[[@pone.0217951.ref018]\]. If the association rule of X → Y is true, then *support*, *confidence*, and *lift* values can be calculated to evaluate the correlation of this rule. S*upport* determines how often a rule, which in this case is the combination of X and Y, is observed in the database. *Support* was measured using the following formula: $$Support = P\left( {X \cap Y} \right) = \left\{ {X \cap Y} \right\}/\left\{ D \right\},$$ where D is the total number of transactions in the database.

The *confidence* of the association rule demonstrates the rule's strength \[[@pone.0217951.ref019]\]. *Confidence* was calculated by the following equation: $$Confidence = P\left( {X \cap Y} \right)/P\left( X \right)$$

*Lift* represents the ratio of probability. Given a rule, X and Y occur together to the multiple of the two individual probabilities for X and Y: $$Lift = P\left( {X \cap Y} \right)/P\left( X \right)P\left( Y \right)$$

*Lift* evaluates the independence of X and Y, and higher *lift* values indicate stronger relationships. If X and Y are independent, *lift* equals 1. If X and Y are positively or negatively correlated, *lift* is \> 1 or \< 1, respectively. Association rule mining was performed utilizing the *arules* package of the R software (version 3.6.0). The parameter *maxlen* (maximum length of itemset/rule, a parameter in the *arules* package) is the maximum size of mined frequent itemsets. To extract association rules efficiently, the thresholds for the optimized *support*, *confidence*, and *maxlen* are defined depending on factors such as size of the data, number of items, and research purpose. In this study, we defined the minimum *support* and *confidence* thresholds as 0.00001 and 0.1, respectively; furthermore, *maxlen* was restricted to 3.

Time-to-onset duration from the JADER database was calculated from the time of the patient's first prescription to the occurrence of the AEs. The median duration, quartiles, and WSPs were used to evaluate the time-to-onset data. The scale parameter α of the Weibull distribution determines the scale of the distribution function. A larger-scale value (α) stretches the distribution, while a smaller scale value shrinks the data distribution. The shape parameter β of the Weibull distribution determines the shape of the distribution function. A larger shape value gives a left-skewed curve, whereas a smaller shape value gives a right-skewed curve. In the analysis of the SRS, the shape parameter β of the Weibull distribution was used to indicate hazards without a reference population as follows. When β was equal to 1, the hazard was estimated to be constant over time. If β was greater than 1 and the 95% CI of β excluded the value 1, the hazard was considered to increase over time. Finally, if β was less than 1 and the 95% CI of β excluded the value 1, the hazard was considered to decrease over time \[[@pone.0217951.ref006], [@pone.0217951.ref010]--[@pone.0217951.ref013]\]. Data analyses were performed using JMP, version 12.0.1 (SAS Institute Inc., Cary, NC, USA).

Results {#sec003}
=======

The JADER database contains 534688 reports submitted from April 2004 to June 2018, and we identified 1218 DIHL events. The top seven AEs were deafness (518 cases, PT code: 10011878), sudden hearing loss (288 cases, PT code: 10061373), hypoacusis (182 cases, PT code: 10048865), deafness neurosensory (108 cases, PT code: 10011891), deafness unilateral (43 cases, PT code: 10048812), auditory disorder (25 cases, PT code: 10003778), and deafness bilateral (23 cases, PT code: 10052556) ([Table 1](#pone.0217951.t001){ref-type="table"}). The lower limits of 95% CI of RORs for platinum compounds, sulfonamides (plain), interferons, antivirals for treatment of HCV infections, other aminoglycosides, papillomavirus vaccines, drugs used in erectile dysfunction, carboxamide derivatives, glycopeptide antibacterials, other quaternary ammonium compounds, and pneumococcal vaccines were over 1. The RORs for other aminoglycosides, other quaternary ammonium compounds, drugs used in erectile dysfunction, and sulfonamides (plain) were 29.4 (22.4--38.6), 18.5 (11.2--30.6), 15.4 (10.6--22.5), and 12.6 (10.0--16.0), respectively ([Table 2](#pone.0217951.t002){ref-type="table"}). The drugs for which the lower limits of 95% CI of RORs were over 1 and RORs were over 10 were as follows: other quaternary ammonium compounds (pancuronium), other aminoglycosides (gentamicin, amikacin, kanamycin, isepamicin, neomycin, tobramycin), drugs used in erectile dysfunction (sildenafil, tadalafil), for sulfonamides (plain) (furosemide), papillomavirus vaccines (human types 6, 11, 16, 18), and macrolides (erythromycin) ([Table 2](#pone.0217951.t002){ref-type="table"}).

Using a stepwise logistic regression model, we examined and selected significant DIHL-related variables among the demographic factors (sex and age-stratified group) and reporting year. The results in the final model indicated significant contributions to DIHL of the ≤ 19 years group (p \< 0.0001), the female and ≤ 19 years group (p \< 0.0001), and the female and 40--59 years group (p = 0.0012). Contrarily, the reporting year did not significantly contribute to DIHL (data not shown). Adjusted RORs for the analyzed groups were as follows: 1.10 for the female group (0.97--1.25, reference: control male group); 2.03 for the ≤ 19 years group (1.68--2.47, reference: ≥ 20 years group); 1.13 for the 40--59 years group (0.97--1.32, reference: ≤ 39 or ≥ 60 years group); 4.32 for the female and ≤ 19 years group (2.94--6.34, reference: male or other age female group); and 0.75 for the female and 40--59 years group (0.55--1.03, reference: male or other age female group). In the mosaic plot, papillomavirus vaccines or other quaternary ammonium compounds were associated with DIHL only in the ≤ 19 years group, causing DIHL in 12.0% and 7.4% of the cases, respectively ([Fig 2](#pone.0217951.g002){ref-type="fig"}).

![Mosaic plot of drug-induced hearing loss.](pone.0217951.g002){#pone.0217951.g002}

Furosemide, ribavirin, and cisplatin were the three drugs most frequently associated with DIHL ([Table 2](#pone.0217951.t002){ref-type="table"}). Therefore, we investigated the dose-dependency of these drugs. The average doses (mean ± standard deviation) of furosemide, ribavirin, and cisplatin for cases with DIHL and without DIHL was 43.7 ± 13.5 and 43.7 ± 2.3 mg (p = 0.9990); 696.2 ± 27.3 and 657.5 ± 2.1 mg (p = 0.1569); and 106.0 ± 12.9 and 88.9 ± 1.0 mg (p = 0.1873), respectively.

Next, we evaluated the possible association between DIHL and demographic data. The mining algorithm identified a set of 22 rules for DIHL ([Table 3](#pone.0217951.t003){ref-type="table"}). {Pancuronium, congenital diaphragmatic hernia} → {hearing loss} demonstrated the highest *lift* value ([Table 3](#pone.0217951.t003){ref-type="table"} (id \[[@pone.0217951.ref001]\]), [Fig 3](#pone.0217951.g003){ref-type="fig"}). The association rules {≤ 19 years, pancuronium} → {hearing loss}, {≤ 19 years, congenital diaphragmatic hernia} → {hearing loss}, and {congenital diaphragmatic hernia} → {hearing loss} exhibited high scores for *lift* and *support* ([Table 3](#pone.0217951.t003){ref-type="table"} (id \[[@pone.0217951.ref005]\]--\[[@pone.0217951.ref007]\]), [Fig 3](#pone.0217951.g003){ref-type="fig"}).

10.1371/journal.pone.0217951.t003

###### Association rule mining for drug-induced hearing loss (sorted by *lift*).

![](pone.0217951.t003){#pone.0217951.t003g}

  id       lhs [^a)^](#t003fn001){ref-type="table-fn"}               rhs [^b)^](#t003fn002){ref-type="table-fn"}   *support*   *confidence*   *lift*
  -------- ----------------------------------------------------- --- --------------------------------------------- ----------- -------------- --------
  \[1\]    {pancuronium, congenital diaphragmatic hernia}        →   {hearing loss}                                2.1E-05     1.00           444.46
  \[2\]    {congenital diaphragmatic hernia, male}               →   {hearing loss}                                1.3E-05     0.47           207.42
  \[3\]    {furosemide, bronchopulmonary dysplasia}              →   {hearing loss}                                1.3E-05     0.47           207.42
  \[4\]    {spironolactone, bronchopulmonary dysplasia}          →   {hearing loss}                                1.3E-05     0.44           194.45
  \[5\]    {≤ 19 years, pancuronium}                             →   {hearing loss}                                2.6E-05     0.42           188.56
  \[6\]    {≤ 19 years, congenital diaphragmatic hernia}         →   {hearing loss}                                2.1E-05     0.42           188.04
  \[7\]    {congenital diaphragmatic hernia}                     →   {hearing loss}                                2.1E-05     0.41           181.08
  \[8\]    {bronchopulmonary dysplasia, low-birth-weight baby}   →   {hearing loss}                                1.3E-05     0.32           141.42
  \[9\]    {pancuronium, female}                                 →   {hearing loss}                                1.1E-05     0.30           133.34
  \[10\]   {spironolactone, low-birth-weight baby}               →   {hearing loss}                                1.3E-05     0.29           129.63
  \[11\]   {cisplatin, neoplasm}                                 →   {hearing loss}                                1.3E-05     0.28           124.45
  \[12\]   {male, deafness unilateral}                           →   {hearing loss}                                1.1E-05     0.25           111.12
  \[13\]   {≤ 19 years, metoformin}                              →   {hearing loss}                                2.1E-05     0.24           106.28
  \[14\]   {furosemide, low-birth-weight baby}                   →   {hearing loss}                                1.3E-05     0.19           84.09
  \[15\]   {deafness unilateral}                                 →   {hearing loss}                                1.3E-05     0.18           77.78
  \[16\]   {pancuronium}                                         →   {hearing loss}                                2.6E-05     0.16           71.52
  \[17\]   {≤ 19 years, bronchopulmonary dysplasia}              →   {hearing loss}                                1.3E-05     0.15           64.82
  \[18\]   {bronchopulmonary dysplasia}                          →   {hearing loss}                                1.3E-05     0.14           62.22
  \[19\]   {neomycin/methylpredonisolone}                        →   {hearing loss}                                2.4E-05     0.14           60.19
  \[20\]   {neomycin/methylpredonisolone, female}                →   {hearing loss}                                1.5E-05     0.13           59.26
  \[21\]   {pancuronium, male}                                   →   {hearing loss}                                1.5E-05     0.12           53.07
  \[22\]   {female, deafness}                                    →   {hearing loss}                                2.4E-05     0.10           45.50

^a)^ lhs: left-hand side (antecedents)

^b)^ rhs: right-hand side (consequents)

![Association rules for drug-induced hearing loss based on the JADER database between April 2004 and June 2018.\
*Support* and *lift* were presented using the R-extension package *arulesViz* which implements novel visualization techniques to explore association rules. The plot arguments in the *arulesViz* were set as follows: method = "graph," measure = "*support*," and shading = "*lift*." The *support* measures were visualized by the size of the circle area. The *lift* measures were presented by the color shade of the circles.](pone.0217951.g003){#pone.0217951.g003}

For the time-to-onset analysis, we extracted combinations for which complete information with regard to the date of treatment initiation and the date of AE onset were available. We evaluated 16 ATC classifications of drugs for which the number of reported cases was more than 10 ([Fig 4](#pone.0217951.g004){ref-type="fig"}). The median durations (interquartile range) for DIHL due to platinum compounds, sulfonamides (plain), interferons, antivirals for treatment of HCV infections, other aminoglycosides, drugs used in erectile dysfunction, carboxamide derivatives, glycopeptide antibacterials, macrolides, and pneumococcal vaccines were 25.5 (7.5--111.3), 80.5 (4.5--143.0), 64.0 (14.0--132.0), 53.0 (9.0--121.0), 11.0 (3.0--26.8), 57.0 (11.8--167.8), 1.5 (0.3--11.5), 5.0 (4.0--13.0), 3.5 (1.3--6.8), and 2.0 (1.0--4.5), respectively. The observed ratios for DIHL due to platinum compounds, sulfonamides (plain), and other aminoglycosides within the first 4 weeks after administration were 51.3% (20/39), 41.7% (10/24), and 80.0% (16/20), respectively. The upper limits of the 95% CI of the WSP β value for carboxamide derivatives were less than 1.

![A box plot and the Weibull shape parameter of drug-induced hearing loss for each ATC classification of drugs.](pone.0217951.g004){#pone.0217951.g004}

Discussion {#sec004}
==========

Our results suggest that AE signals for DIHL were detected for several drugs in the JADER databases. The risks of DIHL due to platinum compounds, sulfonamides (plain), interferons, antivirals for treatment of HCV infections, other aminoglycosides, drugs used in erectile dysfunction, glycopeptide antibacterials, and other quaternary ammonium compounds are stated in the many reports \[[@pone.0217951.ref020]--[@pone.0217951.ref037]\], which agrees with our results. On the other hand, the ROR signals of protein kinase inhibitor, pyrimidine analogues, and monoclonal antibodies were not detected.

Aging is a risk factor for hearing loss \[[@pone.0217951.ref038], [@pone.0217951.ref039]\]. However, multivariate logistic regression analysis indicated that the ≤ 19 years group and the female and ≤ 19 years group may be risk factors for DIHL in our study. To clarify the cause of this discrepancy, we compared the ATC classification types of the drugs administered among the age groups. Other quaternary ammonium compounds (pancuronium and vecuronium) caused DIHL only in the ≤ 19 years group (7.4%) ([Fig 2](#pone.0217951.g002){ref-type="fig"}). In association rule mining, the *lift* and *support* values of {≤ 19 years, pancuronium} → {hearing loss} were high ([Table 3](#pone.0217951.t003){ref-type="table"} (id \[[@pone.0217951.ref005]\]), [Fig 3](#pone.0217951.g003){ref-type="fig"}). Therefore, using pancuronium may largely contribute to DIHL in the ≤ 19 years group. Moreover, papillomavirus vaccines were associated with DIHL only in the ≤ 19 years group (12.0%) ([Fig 2](#pone.0217951.g002){ref-type="fig"}) and the female group, implying their high contribution to DIHL in these patient populations. Our analysis suggested an association between ≤ 19 years age and DIHL. However, through the analysis of standardized patient background based on data subsetting and multivariate logistic regression mitigating the influence of confounding factors \[[@pone.0217951.ref004]--[@pone.0217951.ref006], [@pone.0217951.ref015]--[@pone.0217951.ref017], [@pone.0217951.ref040]\], we may be able to detect the effects of aging. Male sex is a risk factor for hearing loss \[[@pone.0217951.ref038], [@pone.0217951.ref039]\]. However, in the multivariate logistic regression analysis sex was not related to DIHL. This finding may be influenced by different drugs being used in males and females (e.g. papillomavirus vaccines).

Next, we investigated the dose-dependency of furosemide, ribavirin, and cisplatin effects. The p values for ribavirin (p = 0.1569) and cisplatin (p = 0.1873) displayed a tendency of being low. However, there were no significant differences in the average doses between cases with and without DIHL.

Time-to-onset profiles of DIHL have been systematically addressed using the JADER database. Our results suggest that attention should be paid to the possibility of DIHL onset with aminoglycosides and careful observation is recommended soon after the administration for at least 2 weeks. The median durations for DIHL due to platinum compounds and macrolides were 25.5 and 3.5, respectively, and these results support those reported previously \[[@pone.0217951.ref002]\]. The median duration for DIHL due to macrolides and pneumococcal vaccines was a few days and the interquartile range was less than a week ([Fig 4](#pone.0217951.g004){ref-type="fig"}). The median durations for DIHL due to carboxamide derivatives, i.e., carbamazepine, was a few days. The upper limit of the 95% CI of the shape parameter β value for carboxamide derivatives was less than 1, and the hazard was considered to decrease over time ([Fig 4](#pone.0217951.g004){ref-type="fig"}). Therefore, after treatment with macrolides, pneumococcal vaccines, and carbamazepine, it may be necessary for a few days to pay attention to whether hearing loss occurs. On the other hand, special attention for a prolonged duration should be paid to the possibility of DIHL onset due to platinum compounds, sulfonamides (plain), interferons, and antivirals for treatment of HCV infections, and careful observation for at least several months is recommended after the administration of these drugs.

Cisplatin chemotherapy has been widely used in cancer treatment \[[@pone.0217951.ref020]\]. Following cisplatin chemotherapy, the incidence of hearing loss is high and 60% of affected children develop permanent hearing loss \[[@pone.0217951.ref020]\]. The related ROR signal was detected in our study.

It is reported that high trough levels for aminoglycosides (such as gentamicin, tobramycin, and amikacin treatment) and aging may be the risk factors for auditory toxicity \[[@pone.0217951.ref022]\]. Neomycin is considered most ototoxic, followed by gentamicin, kanamycin, and tobramycin while amikacin and netilmicin are considered the least ototoxic \[[@pone.0217951.ref023]\]. Our analysis showed the lower limits of 95% CI of RORs value were \>1 with gentamicin, kanamycin, amikacin, neomycin, isepamicin, tobramycin, and arbekacin, and there are no reports of DIHL due to netilmicin.

The ROR signals were detected for sulfonamides (plain) and vancomycin ([Table 2](#pone.0217951.t002){ref-type="table"}). It is said that high doses of loop diuretics such as furosemide and vancomycin cause ototoxicity \[[@pone.0217951.ref024], [@pone.0217951.ref025]\]. Furthermore, co-administration of loop diuretics or vancomycin can increase aminoglycoside-induced ototoxicity \[[@pone.0217951.ref026]\]. Patients who were administered only sulfonamides (plain) (loop diuretics), only vancomycin, or only other aminoglycosides accounted for 98.7% (76/77 cases), 90.0% (18/20 cases), 94.8% (55/58 cases) of the cases, respectively. In this study, DIHL was observed in most patients who were administered only loop diuretics or only vancomycin. Thus, patients treated with only loop diuretics or only vancomycin should be closely monitored for DIHL.

Several cases of hearing loss during interferon therapy or combination treatment with peginterferon and antiviral for HCV infections (ribavirin) have been reported \[[@pone.0217951.ref027]--[@pone.0217951.ref030]\]. In our study, interferons and ribavirin were coadminstered in 78.1% (57/73 cases) of patients with hearing loss, and 21.9% (16/73 cases) patients were administered interferons alone. Five patients who received ribavirin and not take interferons showed hearing loss. Further studies are necessary on whether interferons themselves are ototoxic and whether coadministration of interferons and ribavirin increases ototoxicity associated with interferons.

ROR signals were detected for papillomavirus vaccines ([Table 2](#pone.0217951.t002){ref-type="table"}). To the best of our knowledge, reports of the association between papillomavirus vaccines and hearing loss are rare. However, cognitive decline is as a frequent papillomavirus vaccine AE \[[@pone.0217951.ref041]\]. Furthermore, hearing loss has been associated with cognitive decline, which improves with the use of hearing aids \[[@pone.0217951.ref042], [@pone.0217951.ref043]\]. Our analysis demonstrated cognitive decline in 59.4% (19/32 cases) of the patients with papillomavirus vaccine-related hearing loss. Thus, hearing loss related to papillomavirus vaccines may be partially associated with cognitive decline.

Phosphodiesterase 5 (PDE5) inhibitors such as sildenafil are prescribed for erectile dysfunction \[[@pone.0217951.ref044]\]. Case studies and retrospective chart reviews have suggested that PDE5 inhibitors may induce sensorineural hearing loss \[[@pone.0217951.ref031]--[@pone.0217951.ref033]\]. On the contrary, sildenafil was reported to not have any effect on hearing in a mouse model \[[@pone.0217951.ref044]\]. The pathophysiology and mechanism of PDE5 inhibitor-induced hearing loss are not yet well known. Our analysis showed that significant ROR signals were detected with drugs used in erectile dysfunction, and the lower limits of 95% CI of RORs value were \>1 with tadalafil and sildenafil ([Table 2](#pone.0217951.t002){ref-type="table"}). This may indicate that PDE5 inhibitors are a risk factor of DIHL. Erectile dysfunction may be associated with age \[[@pone.0217951.ref045]\]. The ototoxicity associated with PDE5 inhibitors may enhance age-related hearing loss.

Sensorineural hearing loss occurs in up to 60% of survivors of neonatal congenital diaphragmatic hernia \[[@pone.0217951.ref035]\]. Furthermore, prolonged pancuronium use may be associated with sensorineural hearing loss in patients with congenital diaphragmatic hernia \[[@pone.0217951.ref035], [@pone.0217951.ref036]\]. Contrarily, in congenital diaphragmatic hernia patients, only age independent association of sensorineural hearing loss has been reported, which did not involve longer aminoglycosides, furosemide, and pancuronium treatments \[[@pone.0217951.ref046]\]. Our analysis showed that hearing loss occurred in 43.3% of the patients (13/30 cases) with AEs due to pancuronium, and the ROR signal was detected ([Table 2](#pone.0217951.t002){ref-type="table"}). The association rule {pancuronium, congenital diaphragmatic hernia} → {hearing loss} demonstrated the highest *lift* value ([Table 3](#pone.0217951.t003){ref-type="table"} (id \[[@pone.0217951.ref001]\]), [Fig 3](#pone.0217951.g003){ref-type="fig"}): Furthermore, {≤ 19 years, pancuronium} → {hearing loss}, {≤ 19 years, congenital diaphragmatic hernia} → {hearing loss}, and {congenital diaphragmatic hernia} → {hearing loss} exhibited high *lift* and *support* scores ([Table 3](#pone.0217951.t003){ref-type="table"} (id \[[@pone.0217951.ref005]--[@pone.0217951.ref007]\]), [Fig 3](#pone.0217951.g003){ref-type="fig"}). Therefore, not only age, but also pancuronium administration may be risk factors for sensorineural hearing loss in patients with congenital diaphragmatic hernia, highlighting the need for monitoring after pancuronium treatment in this patient group.

In the JADER database, duplicate data may be present due to follow-up reports on a case or different individuals disclosing the same patient case. It is recommended to identify duplicate patient reports originating from different sources and to exclude them from the analysis. For example, for the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we followed the agency's recommendations ([www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects](http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects)) and adopted the most recent case number to identify duplicate patient reports and exclude them from the analysis. However, there is no key code to identify duplicate reports in the JADER database, rendering their removal challenging. The PMDA has introduced an evaluation method based on a match score for duplicate detection in the JADER database \[[@pone.0217951.ref047]\]. However, this analytical approach is currently not widely accepted, and most JADER database reports do not distinguish between duplicates. Therefore, we did not further investigate this topic in the current study.

SRSs are subject to over-reporting, under-reporting, missing data, exclusion of healthy individuals, lack of denominators, and presence of confounding factors \[[@pone.0217951.ref003]\]. The JADER database is an SRS and does not contain sufficient information regarding patient background to allow proper evaluation. Furthermore, many factors influence DIHL. Thus, increased reactive oxygen species contribute to cisplatin-induced hearing loss \[[@pone.0217951.ref021]\]. Viral infections result in hearing loss by direct damage to inner ear structures induction inflammatory responses, and increased susceptibility to bacterial or fungal infections \[[@pone.0217951.ref048]\]. Noise induces synaptic loss between inner hair cells and spiral ganglion neurons and may be a key pathological factor for sensorineural hearing loss \[[@pone.0217951.ref049]\]. The effects of these factors on DIHL are difficult to evaluate by using the SRS data set. Future investigations should conduct more detailed analysis focused on DIHL.

Despite the limitations inherent to spontaneous reporting, risk factors for DIHL were identified after adjustment for patient differences using appropriate analysis methods. Our results, based on the evaluation of JADER, are consistent with previous reports and provide essential information to improve our understanding of this issue. Furthermore, our study indicates the importance of comparing safety profiles of newer and traditional drugs using post-marketing real-world data. Information from the JADER dataset may be considered of complementary value. However, these data may be particularly beneficial to prescribers.

Conclusions {#sec005}
===========

To best of our knowledge, this was the first study to evaluate DIHL and the responsible drugs using an SRS analysis strategy. Based on RORs, we demonstrated the potential DIHL risk associated with numerous drugs including platinum compounds, sulfonamides (plain) (loop diuretics), interferons, ribavirin, other aminoglycosides, papillomavirus vaccines, drugs used in erectile dysfunction, vancomycin, erythromycin, and pancuronium. Our finding indicated that patients with congenital diaphragmatic hernia should be monitored after pancuronium administration. Patients treated with aminoglycosides should be closely observed for DIHL for at least 2 weeks. After the administration of macrolides, pneumococcal vaccines, and carbamazepine, it may be necessary to monitor individuals for hearing loss for a few days. However, careful observation for at least several months is recommended after the administration of platinum compounds, sulfonamides (plain), interferons, and antivirals for treatment of HCV infections. Despite the inherent limitations associated with SRS data, we believe that our findings represent a valuable contribution to the clinical knowledge and will help improve the management of DIHL.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.
